Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Inclusion Criteria: * Histologically/cytologically confirmed advanced or metastatic solid tumors who have failed standard therapy or for whom no effective standard anti-cancer therapy exists * Documented PIK3CA mutations in all patients in dose escalation and expansion with or without documented genetic alterations in FGFR depending upon dose expansion cohort (either local or central determination) * Measurable disease defined by RECIST v1.1 * ECOG performance status of ≤2 Exclusion Criteria: * Prior PI3Ki or selective FGFR inhibitor treatment (for patients enrolled to expansion part) * Colorectal cancer (for patients enrolled to expansion part) * Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L, history of clinically significant gestational diabetes mellitus or documented steroid-induced diabetes mellitus * Use of medications that increase serum levels of phosphorus and/or calcium * Inorganic phosphorus outside of normal limits * Total and ionized serum calcium outside of normal limits